Tags

Type your tag names separated by a space and hit enter

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Int J Gynecol Cancer. 2011 Aug; 21(6):1024-31.IJ

Abstract

INTRODUCTION

The objective of the study was to evaluate the prognostic effect of p53, PTEN, and concomitant p53 PTEN status on clinicopathologic features, recurrent disease, and disease-free survival (DFS) of 131 patients in FIGO stages I to II with epithelial ovarian cancer.

METHODS

The technique of tissue microarray and immunohistochemistry was used for the detection of positivity of the biologic markers p53 and PTEN.

RESULTS

In the complete series, the 5-year DFS rate was 68%, and the overall survival rate was 71%. Positive staining for p53 and PTEN was detected in 25% and 22% of cases, respectively. Positivity of p53 was associated with tumor grade in the total series but not in the subgroup of serous tumors. In survival analysis, there was worse survival (P = 0.003) in the group of patients with p53-positive tumors compared with the group of patients with p53-negative tumors with DFS of 62% and 82%, respectively. Furthermore, DFS was 15% for the subgroup of patients with concomitant p53-positivity and PTEN-negativity of tumors compared with DFS of 62% for others in 1 group (p53+PTEN+, p53-PTEN+, p53-PTEN-) at 100 months. The difference was highly significant (P = 0.006). FIGO stage (odds ratio = 8.0) and p53 PTEN status (odds ratio = 0.6) were predictive factors for tumor recurrences in a logistic regression and prognostic factors with hazard ratios (HRs) of 4.0 and 0.6, respectively, in a multivariate Cox regression analysis. In a separate Cox regression analysis, FIGO stage (HR = 3.6) and p53 status (HR = 2.0) were prognostic factors for DFS. For serous tumors (n = 51) recurrent disease was associated with FIGO stage (P = 0.013), and p53 loss (P = 0.029) but not with FIGO grade (P = 0.169).

CONCLUSIONS

p53 status divides ovarian carcinomas into 2 subgroups after prognosis, also in serous tumors. Presence of PTEN in p53-positive tumors seems to protect from bad prognosis and absence of PTEN seems to worsen prognosis in early stages.

Authors+Show Affiliations

Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. ingiridur.skirnisdottir@kbh.uu.seNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21792012

Citation

Skírnisdóttir, Ingirídur, and Tomas Seidal. "Prognostic Impact of Concomitant P53 and PTEN On Outcome in Early Stage (FIGO I-II) Epithelial Ovarian Cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, vol. 21, no. 6, 2011, pp. 1024-31.
Skírnisdóttir I, Seidal T. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(6):1024-31.
Skírnisdóttir, I., & Seidal, T. (2011). Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 21(6), 1024-31. https://doi.org/10.1097/IGC.0b013e31821dc906
Skírnisdóttir I, Seidal T. Prognostic Impact of Concomitant P53 and PTEN On Outcome in Early Stage (FIGO I-II) Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2011;21(6):1024-31. PubMed PMID: 21792012.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. AU - Skírnisdóttir,Ingirídur, AU - Seidal,Tomas, PY - 2011/7/28/entrez PY - 2011/7/28/pubmed PY - 2012/3/7/medline SP - 1024 EP - 31 JF - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society JO - Int J Gynecol Cancer VL - 21 IS - 6 N2 - INTRODUCTION: The objective of the study was to evaluate the prognostic effect of p53, PTEN, and concomitant p53 PTEN status on clinicopathologic features, recurrent disease, and disease-free survival (DFS) of 131 patients in FIGO stages I to II with epithelial ovarian cancer. METHODS: The technique of tissue microarray and immunohistochemistry was used for the detection of positivity of the biologic markers p53 and PTEN. RESULTS: In the complete series, the 5-year DFS rate was 68%, and the overall survival rate was 71%. Positive staining for p53 and PTEN was detected in 25% and 22% of cases, respectively. Positivity of p53 was associated with tumor grade in the total series but not in the subgroup of serous tumors. In survival analysis, there was worse survival (P = 0.003) in the group of patients with p53-positive tumors compared with the group of patients with p53-negative tumors with DFS of 62% and 82%, respectively. Furthermore, DFS was 15% for the subgroup of patients with concomitant p53-positivity and PTEN-negativity of tumors compared with DFS of 62% for others in 1 group (p53+PTEN+, p53-PTEN+, p53-PTEN-) at 100 months. The difference was highly significant (P = 0.006). FIGO stage (odds ratio = 8.0) and p53 PTEN status (odds ratio = 0.6) were predictive factors for tumor recurrences in a logistic regression and prognostic factors with hazard ratios (HRs) of 4.0 and 0.6, respectively, in a multivariate Cox regression analysis. In a separate Cox regression analysis, FIGO stage (HR = 3.6) and p53 status (HR = 2.0) were prognostic factors for DFS. For serous tumors (n = 51) recurrent disease was associated with FIGO stage (P = 0.013), and p53 loss (P = 0.029) but not with FIGO grade (P = 0.169). CONCLUSIONS: p53 status divides ovarian carcinomas into 2 subgroups after prognosis, also in serous tumors. Presence of PTEN in p53-positive tumors seems to protect from bad prognosis and absence of PTEN seems to worsen prognosis in early stages. SN - 1525-1438 UR - https://www.unboundmedicine.com/medline/citation/21792012/Prognostic_impact_of_concomitant_p53_and_PTEN_on_outcome_in_early_stage__FIGO_I_II__epithelial_ovarian_cancer_ L2 - https://ijgc.bmj.com/lookup/pmidlookup?view=long&pmid=21792012 DB - PRIME DP - Unbound Medicine ER -